Technologies for drug discovery are constantly evolving. Significant developments within the last 20 years range from the development of DNA-encoded libraries for hit finding and even hit-to-lead optimisation to the reinvigoration of irreversible inhibitors resulting in innovative oncology drugs such as osimertinib and sotorasib.
This course will cover advanced methods, new technologies and tools available for medicinal chemists, with a focus on oncology drug discovery, including fragment based-drug discovery, DNA-encoded library technologies, covalent drug discovery and small molecules that target RNA. The course will finish with a series of oncology case studies successfully utilising these drug discovery technologies for the development of clinical candidates and marketed drugs.
More information can be found on the website of the symposium.
